Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.
Also in this 8-page issue: Dept. of Justice, Congress to investigate Merck and FDA actions on Vioxx; FDA asks IOM to study its monitoring system for approved drugs.
NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.
St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.
Funding opportunities listed.
Trending Stories
- Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- 2024 Karnofsky Award winner Lillian Siu talks about her career in phase I studies, ctDNA, and her mentor’s “evil red pencil”
- Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity
- Canine cancers as models: We have barely tapped the full potential of comparative oncology